Captopril
- Generic Name
- Captopril
- Drug Type
- Small Molecule
- Chemical Formula
- C9H15NO3S
- CAS Number
- 62571-86-2
- Unique Ingredient Identifier
- 9G64RSX1XD
- Background
Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
- Indication
For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
- Associated Conditions
- Aldosteronism, Anatomic renal artery stenosis, Congestive Heart Failure (CHF), Diabetic Nephropathy, Heart Failure, Hypertension, Hypertensive crisis, Non-STEMI Acute Coronary Syndrome, Raynaud's Phenomenon, Ejection fraction of 40% or less Left ventricular dysfunction
Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity
- Conditions
- Primary Aldosteronism
- Interventions
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2009-06-10
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT00917345
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 717
- Registration Number
- NCT00853385
- Locations
- 🇬🇧
Pfizer Investigational Site, Dudley, West Midlands, United Kingdom
Rapid Versus Prolonged Inpatient Up-Titration of Captopril
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2008-08-27
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 50
- Registration Number
- NCT00742040
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
- Conditions
- Carcinoma, Adenosquamous CellCarcinoma, Squamous CellCarcinoma, Large CellCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 583
- Registration Number
- NCT00673049
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy
- Conditions
- Diabetic Nephropathy
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT00663949
- Locations
- 🇮🇷
Shiraz University of Medical Sciences ,Nemazee and Faghihi Hospital, Shiraz, Fars, Iran, Islamic Republic of
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00660309
- Locations
- 🇺🇸
Novartis Investigator Site, Boston, Massachusetts, United States
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
- Conditions
- Heart FailureVentricular Dysfunction, Left
- Interventions
- Drug: DiureticsDrug: HF treatment according to Swedish guidelinesProcedure: Blood samplesProcedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT00391846
- Locations
- 🇸🇪
Research Site, Vaxjo, Sweden
Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis
- Conditions
- Aortic Stenosis
- Interventions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2008-09-03
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 64
- Registration Number
- NCT00252317
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Kbh Ø, Denmark
Treatment of Supine Hypertension in Autonomic Failure
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDietary Supplement: L-arginineOther: Head-up tilt.Other: Local heat stress
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 152
- Registration Number
- NCT00223717
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00086723
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.